ALDOXORUBICIN
| 中文名称 | ALDOXORUBICIN |
|---|---|
| 中文同义词 | (E)-N'-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-氨基-5-羟基-6-甲基-2-四氢吡喃基]氧基]-2,5,12-三羟基-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢-2-并四苯基]-2-羟基亚乙基]-6-(2,5-二氧代-2,5-二氢-1-吡咯基)己酰肼;(E)-N'-(1-((2S,4S)-4-(((2R,4S,5S,6S)-4-氨基-5-羟基-6-甲基四氢-2H-吡喃-2-基基)氧基)-2,5,12-三羟基-7-甲氧基-6,11-二氧代-1,2,3,4,6,11-六氢四乙酰-2-基)-2-羟基亚乙基)-6-(2-,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰肼;化合物 T11090L;化合物 ALDOXORUBICIN;ALDOXORUBICIN/1361644-26-9;INNO-206【CAS:1361644-26-9】【规格:10mg】【纯度:≥98%】;INNO-206【CAS：1361644-26-9】【规格：10mg】【纯度：≥98%】 |
| 英文名称 | INNO206 |
| 英文同义词 | Aldoxorubicin;Aldoxorubicin (INNO-206);N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide;(E)-N’-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide;Aldoxorubicin Aldoxorubicin;1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide;DoxorubicinImpurity16Trifluoroacetate;N'-((E)-1-((2S,4S)-4-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide |
| CAS号 | 1361644-26-9 |
| 分子式 | C37H42N4O13 |
| 分子量 | 750.75 |
| EINECS号 | |
| 相关类别 | 细胞周期 |
| Mol文件 | 1361644-26-9.mol |
| 结构式 |  |
ALDOXORUBICIN 性质
| 密度 | 1.60±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -80°, stored under nitrogen,unstable in solution, ready to use. |
| 溶解度 | 二甲基亚砜：75 mg/mL（99.90 mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 7.36±0.60(Predicted) |
| 颜色 | 紫至紫红色 |
|
Topoisomerase II
|
Daunorubicins/Doxorubicins
|
Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion.
Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-16261 | ALDOXORUBICIN Aldoxorubicin | 1361644-26-9 | 5mg | 997元 |
| 2025/12/22 | HY-16261 | ALDOXORUBICIN Aldoxorubicin | 1361644-26-9 | 10mg | 1740元 |